利拉鲁肽对2型糖尿病骨质疏松大鼠miRNA-19a、miRNA-144及骨密度的影响

目的分析利拉鲁肽对2型糖尿病骨质疏松(DOP)大鼠miRNA-19a、miRNA-144及骨密度的影响。方法采用随机数表法将50只大鼠随机分为正常组、去势对照组、模型组及给药组,模型组及给药组构建2型DOP大鼠模型;去势对照组摘除双侧卵巢,后正常组、去势对照组及模型组使用生理盐水干预,给药组使用利拉鲁肽治疗;治疗结束后采集大鼠血液样本,检测血糖、胰岛素、Cad-11、IRS1、miRNA-19a及miRNA-144水平;使用双能X线骨密度检测仪检测腰椎、全身、骨盆及股骨骨密度。结果给药组血糖、miRNA-19a、miRNA-144、Cad-11及IRS1水平均明显优于模型组及去势对照组;给药组大鼠各部位骨密度明显高于去势对照组和模型组。结论利拉鲁肽可抑制糖尿病大鼠骨密度的降低,其作用可能与降低2型DOP大鼠miRNA-19a、miRNA-144水平有关。

Effects of liraglutide on microRNA-19a, microRNA-144, and bone mineral density in osteoporotic rats with type 2 diabetes mellitus

Objective To analyze the effect of liraglutide on miRNA-19a, miRNA-144, and bone density in rats with type 2 diabetes and osteoporosis (DOP). Methods Random number table method was used to randomly divide 50 rats into normal group, castration control group, model group, and drug administration group. DOP rat model was constructed in model group and drug administration group. Rats were removed bilateral ovaries in castration control group. Rats in the normal group, castration control group, and model group were treated with normal saline. Rats in the drug group received liraglutide. After the treatment, blood samples of rats were collected to detect levels of blood glucose, insulin, Cad-11, IRS1, miRNA-19a, and miRNA-144. Bone mineral density of the lumbar spine, whole body, pelvis, and femur was detected using dual-energy X-ray absorptiometry. Results The levels of blood glucose, miRNA-19a, miRNA-144, Cad-11, and IRS1 in the drug administration group were significantly better than those in the model group and castration control group. Bone mineral density of the rats in the drug administration group was significantly higher than that in the castration control group and model group. Conclusion Liraglutide inhibits the decrease of bone mineral density in diabetic rats, and its effect may be related to the reduction of miRNA-19a and miRNA-144 levels in type 2 DOP rats.